JP6887492B6 - 遺伝子改変細胞で使用するための共刺激ドメイン - Google Patents

遺伝子改変細胞で使用するための共刺激ドメイン Download PDF

Info

Publication number
JP6887492B6
JP6887492B6 JP2019518049A JP2019518049A JP6887492B6 JP 6887492 B6 JP6887492 B6 JP 6887492B6 JP 2019518049 A JP2019518049 A JP 2019518049A JP 2019518049 A JP2019518049 A JP 2019518049A JP 6887492 B6 JP6887492 B6 JP 6887492B6
Authority
JP
Japan
Prior art keywords
cells
cell
car
domain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518049A
Other languages
English (en)
Japanese (ja)
Other versions
JP6887492B2 (ja
JP2019528769A (ja
JP2019528769A5 (enExample
Inventor
ジャンツ，デレック
マーティン，アーロン
サンマン，ジェフリー
マクラウド，ダニエル，ティー．
Original Assignee
プレシジョン バイオサイエンシズ，インク．
プレシジョン バイオサイエンシズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレシジョン バイオサイエンシズ，インク．, プレシジョン バイオサイエンシズ，インク． filed Critical プレシジョン バイオサイエンシズ，インク．
Publication of JP2019528769A publication Critical patent/JP2019528769A/ja
Publication of JP2019528769A5 publication Critical patent/JP2019528769A5/ja
Priority to JP2021083808A priority Critical patent/JP7106715B2/ja
Publication of JP6887492B2 publication Critical patent/JP6887492B2/ja
Application granted granted Critical
Publication of JP6887492B6 publication Critical patent/JP6887492B6/ja
Priority to JP2022112159A priority patent/JP2022160443A/ja
Priority to JP2024013162A priority patent/JP2024059633A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seal Device For Vehicle (AREA)
JP2019518049A 2016-10-04 2017-10-04 遺伝子改変細胞で使用するための共刺激ドメイン Active JP6887492B6 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021083808A JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662403880P 2016-10-04 2016-10-04
US62/403,880 2016-10-04
US201762501475P 2017-05-04 2017-05-04
US62/501,475 2017-05-04
US201762556199P 2017-09-08 2017-09-08
US62/556,199 2017-09-08
PCT/US2017/055133 WO2018067697A1 (en) 2016-10-04 2017-10-04 Co-stimulatory domains for use in genetically-modified cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021083808A Division JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン

Publications (4)

Publication Number Publication Date
JP2019528769A JP2019528769A (ja) 2019-10-17
JP2019528769A5 JP2019528769A5 (enExample) 2020-11-12
JP6887492B2 JP6887492B2 (ja) 2021-06-16
JP6887492B6 true JP6887492B6 (ja) 2021-07-14

Family

ID=60382586

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019518049A Active JP6887492B6 (ja) 2016-10-04 2017-10-04 遺伝子改変細胞で使用するための共刺激ドメイン
JP2021083808A Active JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A Pending JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A Pending JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021083808A Active JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A Pending JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A Pending JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン

Country Status (8)

Country Link
US (4) US11286291B2 (enExample)
EP (3) EP3523326B1 (enExample)
JP (4) JP6887492B6 (enExample)
AU (4) AU2017338846B2 (enExample)
CA (1) CA3039014A1 (enExample)
DK (2) DK3757120T3 (enExample)
ES (2) ES2811500T3 (enExample)
WO (1) WO2018067697A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877291A (zh) 2014-04-10 2021-06-01 西雅图儿童医院 (Dba西雅图儿童研究所) 基因修饰的t细胞产品、其制备方法和用途
HK1256087A1 (zh) 2015-08-07 2019-09-13 Seattle Children's Hospital, Dba Seattle Children's Research Institute 用於实体瘤靶向的双特异性cart细胞
ES2811500T3 (es) * 2016-10-04 2021-03-12 Prec Biosciences Inc Dominios coestimuladores para su uso en células genéticamente modificadas
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
WO2018201144A1 (en) * 2017-04-28 2018-11-01 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
US11434290B2 (en) * 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
KR20240122580A (ko) 2019-04-03 2024-08-12 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US20220204994A1 (en) 2019-04-05 2022-06-30 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CA3148179A1 (en) 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
US20220411479A1 (en) 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
US20230036065A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20230346937A1 (en) * 2020-02-13 2023-11-02 Beijing Immunochina Pharmaceuticals Co., Ltd. Optimization of chimeric antigen receptor
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US20230190780A1 (en) * 2020-05-15 2023-06-22 Precision Biosciences, Inc. Methods for immunotherapy
WO2021231959A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
AU2021300615A1 (en) * 2020-06-30 2023-02-02 The University Court Of The University Of Edinburgh Transgene expression system
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022266192A1 (en) * 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
IL313935A (en) 2021-12-30 2024-08-01 Tr1X Inc CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
AU2024206812A1 (en) 2023-01-05 2025-08-14 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2026015450A1 (en) 2024-07-06 2026-01-15 Tr1X, Inc. Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CA2181548C (en) 1994-01-18 2009-11-03 Carlos F. Barbas, Iii Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
DE69535829D1 (de) 1994-08-20 2008-10-16 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2004037977A2 (en) 2002-09-05 2004-05-06 California Institute Of Thechnology Use of chimeric nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
CA2626262C (en) 2005-10-18 2015-09-08 Homme W. Hellinga Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP3578646A3 (en) 2007-10-31 2020-03-18 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
EP3456826B1 (en) 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PT3613439T (pt) * 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
US20180134795A1 (en) 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
JP6736540B2 (ja) * 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
BR112017001818A2 (pt) 2014-07-29 2017-11-21 Pfizer receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
WO2016036746A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
MX2017004603A (es) * 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
EP3227323B1 (en) * 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
IL320860A (en) 2014-12-19 2025-07-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
US20180002435A1 (en) * 2015-01-26 2018-01-04 Cellectis mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
ES2811500T3 (es) * 2016-10-04 2021-03-12 Prec Biosciences Inc Dominios coestimuladores para su uso en células genéticamente modificadas
KR20240122580A (ko) * 2019-04-03 2024-08-12 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US20220411479A1 (en) * 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
US20230036065A1 (en) * 2019-12-06 2023-02-02 Precision Biosciences, Inc. Methods for cancer immunotherapy

Also Published As

Publication number Publication date
AU2017338846B2 (en) 2020-09-24
US20240018215A1 (en) 2024-01-18
JP6887492B2 (ja) 2021-06-16
AU2025200717A1 (en) 2025-02-20
US20190233500A1 (en) 2019-08-01
ES2811500T3 (es) 2021-03-12
DK3757120T3 (da) 2022-07-25
EP3757120B1 (en) 2022-05-11
JP2022160443A (ja) 2022-10-19
AU2020286323B2 (en) 2023-02-16
US20200399346A1 (en) 2020-12-24
US20200031904A1 (en) 2020-01-30
US11286291B2 (en) 2022-03-29
WO2018067697A1 (en) 2018-04-12
EP3757120A1 (en) 2020-12-30
CA3039014A1 (en) 2018-04-12
JP2024059633A (ja) 2024-05-01
JP2019528769A (ja) 2019-10-17
EP3523326A1 (en) 2019-08-14
JP2021151235A (ja) 2021-09-30
US10800833B2 (en) 2020-10-13
AU2020286323A1 (en) 2021-01-21
DK3523326T3 (da) 2020-08-03
EP3523326B1 (en) 2020-06-03
JP7106715B2 (ja) 2022-07-26
ES2925644T3 (es) 2022-10-19
AU2017338846A1 (en) 2019-04-18
EP3757120B8 (en) 2022-06-15
AU2023202905A1 (en) 2023-07-27
EP4115951A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
JP6887492B6 (ja) 遺伝子改変細胞で使用するための共刺激ドメイン
US20230174621A1 (en) Modified epidermal growth factor receptor peptides for use in genetically-modified cells
US20220228115A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
US12448613B2 (en) Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
JP2025131624A (ja) ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ
HK40035810A (en) Co-stimulatory domains for use in genetically-modified cells
HK40035810B (en) Co-stimulatory domains for use in genetically-modified cells
HK40012578A (en) Co-stimulatory domains for use in genetically-modified cells
HK40012578B (en) Co-stimulatory domains for use in genetically-modified cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201002

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210518

R150 Certificate of patent or registration of utility model

Ref document number: 6887492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250